Botanix Secures Second Sofdra API Supplier to Cut Costs and De-Risk Supply Chain

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.

Botanix Pharmaceuticals has signed a term sheet with PPL Pharma Solutions Riverview LLC, under which Piramal will begin development services and act as an alternate commercial supplier of sofpironium bromide, the active pharmaceutical ingredient in Sofdra. The immediate start of technical transfer and planned definitive supply agreement are expected to de-risk Botanix’s supply chain for Sofdra and potentially cut cost of goods sold by 25% to 40%, boosting gross profit and strengthening the company’s commercial positioning in the hyperhidrosis treatment market.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a U.S.-based commercial dermatology company headquartered in Philadelphia and Phoenix, focused on treatments for skin disorders. Its lead product, Sofdra, recently received FDA approval as the first and only new chemical entity indicated for primary axillary hyperhidrosis, offering a novel, safe and effective option for patients with few existing therapies.

Average Trading Volume: 15,379,808

Technical Sentiment Signal: Sell

Current Market Cap: A$92.29M

Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.